2026 American Academy of Neurology Abstract Website

Disclosures for "First-line Induction Therapy for Hospitalized Patients with Primary CNS Vasculitis"

Dr. DiBiase has nothing to disclose.
Dr. Kim has nothing to disclose.
Miss Singh has nothing to disclose.
Mr. Shramuk has nothing to disclose.
Dr. Dua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. Dr. Dua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Dua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Dua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for abbvie.
Dr. Dixit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Servier.
Dr. Balabanov has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Balabanov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Balabanov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Balabanov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Balabanov has received research support from NextCure. The institution of Dr. Balabanov has received research support from Biogen. The institution of Dr. Balabanov has received research support from NINDS.
Dr. Graham has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Graham has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Graham has received research support from F. Hoffman-La Roche Ltd. The institution of Dr. Graham has received research support from Novartis.